“SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular Protection from an Oral GLP-1 in High-Risk Type 2 Diabetes”. Diabzen 4, no. 19 (July 7, 2026): 38–39. Accessed July 28, 2026. https://thediabzen.com/index.php/d/article/view/62.